UK's NICE recommends Takeda's Entyvio for Crohn's disease
The UK’s National Institute for health and Care Excellence (NICE) has recommended Entyvio (vedolizumab) from Takeda Pharmaceutical (TYO: 4502), Japan's largest drugmaker, for adults with moderate to severe Crohn’s disease who have either failed or were intolerant to an anti-TNF.
The NICE recommends vedolizumab, a 30-minute intravenous infusion given every eight weeks at a fixed dose of 300mg, and is the first gut-selective treatment for Crohn’s disease. It has particularly recognized the value of the therapy as a cost-effective treatment that provides remission from symptoms, when the annual UK cost per patient in relapse is estimated at £10,513 ($16,374).
Vedolizumab works selectively in the gut to help block the entry of white blood cells, reducing inflammation and associated symptoms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze